Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.5 , No. 1, Publication Date: Jul. 23, 2019, Page: 1-5
 and control group (B), 100 in each group. Patients in group B received Simvastatin, and patients in group A received Chuanxiongsu for 8-week treatment. The levels of blood pressure and blood lipid were measured before and after treatment for two groups of patients. And 100 healthy volunteers served as healthy control group (C). Results Compared with pretherapy, the level of blood lipid was significantly different after 8 weeks treatment in both groups (P<0.01), while no significant discrepancy was observed (P>0.05) between the two groups. Blood pressure decreased more in group A than group B, with statistic significance (P<0.01), after treatment. Meanwhile, group A experienced less side-effect than group B. Conclusion Chuanxiongsu, as an alternative to Simvastatin, can markedly improve blood lipid metabolism, effectively reduce the level of blood pressure to some extent that alleviates development of prehypertension, and is safer than Simvastatin. Totally, curative effect of Chuanxiongsu is better than that of Simvastatin, thus Chuanxiongsu is suggested to be applied in treatment of prehypertension patients with hyperlipemia.&picture=http://www.aascit.org/aascit/decorators/img/journal/979.jpg)
| [1] | Xiaojun Wang, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [2] | Liemin Zhang, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [3] | Jianqing Xia, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [4] | Ping Wang, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [5] | Jie Hou, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [6] | Yan Xue, Department of Internal Medicine, Hubei Provincial Women’s and Children’s Hospital, Wuhan, China. |
| [7] | Zhiping Xu, Department of Internal Medicine, General Hospital of Xinzhou District, Wuhan, China. |
Objective to observe the clinical effects of Chuanxiongsu in treatment of prehypertensive patients with hyperlipemia, and to investigate the possible mechanism of action. Methods A total of 200 cases of prehypertension with hyperlipemia were selected as our subjects, who were in out-patients clinic of Hubei Provincial Women’s & Children’s Hospital and Xinzhou District General Hospital in Wuhan, and were randomly divided into treatment group (A) and control group (B), 100 in each group. Patients in group B received Simvastatin, and patients in group A received Chuanxiongsu for 8-week treatment. The levels of blood pressure and blood lipid were measured before and after treatment for two groups of patients. And 100 healthy volunteers served as healthy control group (C). Results Compared with pretherapy, the level of blood lipid was significantly different after 8 weeks treatment in both groups (P<0.01), while no significant discrepancy was observed (P>0.05) between the two groups. Blood pressure decreased more in group A than group B, with statistic significance (P<0.01), after treatment. Meanwhile, group A experienced less side-effect than group B. Conclusion Chuanxiongsu, as an alternative to Simvastatin, can markedly improve blood lipid metabolism, effectively reduce the level of blood pressure to some extent that alleviates development of prehypertension, and is safer than Simvastatin. Totally, curative effect of Chuanxiongsu is better than that of Simvastatin, thus Chuanxiongsu is suggested to be applied in treatment of prehypertension patients with hyperlipemia.
Keywords
Chuanxiongsu Tablets, Simvastatin Capsule, Lipid, Blood Pressure, Prehypertension, Hyperlipemia, Comparative Effectiveness Research
Reference
| [01] | Yan Wenzhen, Wang Ruiying, Huang Shutian. Association of carotid artery intima-media thickness and blood pressure variation in patients with prehypertension [J]. Clinical Medicine of China, 2015, 31 (4): 322-325. |
| [02] | Liu Lisheng. 2010 Chinese guidelines for the management of hypertension [J]. Chin J Hypertens, 2011, 18 (8): 701-743. |
| [03] | Wu Xun. The 4th academic conference on cerebrovascular diseases [J]. Stroke and Nervous Diseases, 1997, 4 (2): 105-109. |
| [04] | Writing group of 2011 Chinese blood pressure monitoring. 2010 Chinese guidelines for blood pressure monitoring [J]. Chinese Journal of Cardiology, 2011, 19 (12): 1101-1115-413. |
| [05] | ZHU Ying, HUANG Ke-yu, CHEN Hai, et al. The relationship between high normal blood pressure and new carotid artery plaques [J]. Chin J Hypertens, 2015, 30 (5): 428-432. |
| [06] | LI Jia-Ming, ZHAO Yong-Hai, MA Feng-Shi, et al. Synthesis of Ligustrazine-Aromatic Acid Derivatives and Their Inhibitory Effect on Platelet Aggregation [J]. Chinese Journal of Organic Chemistry, 2008, 33 (9): 578-583. |
| [07] | HUANG Wen-dong, YANG Yong-fei, CHEN Jian-wen, et al. Synergism of tanshinol and tetramethylpyrazine on cardiovascular system in rats [J]. Chinese Pharmacological Bulletin, 2013, 29 (3): 432-436. |
| [08] | JIANG Hong, SHI Guang-fei, ZHU Zhu. Advance research of effect of Ligustrazine on cardiovascular system [J]. Chin J Clin Pharmacol Ther 2007, 11 (5): 481-483., |
| [09] | PAN Rui. Clinical observation on TMP Salvia Injection combined with Conventional Therapy in Treatment of 72 Cases of IV Stage Diabetic Nephropathy [J]. J Henan Univ Sci Tech (Med Sci), 2015, 33 (3): 200-202. |
| [10] | CAI Li-li, LI Jing-hui, XU Jian-gang, et al. Effect of Danshen Ligustrazine for injection on blood rheology, hs-CRP and fat metabolism on elderly patients with unstable angina pectoris [J]. Practical Pharmacy and Clinical Remedies, 2014, 17 (3): 267-270. |
| [11] | ZHANG Wei-min, LI Rui-fang, Fu Yin-feng, et al. Protect effects of tetramethylprazine (TMP) on cardiomyocytes apoptosis and injury in Adriamycin-induced acute heart failure mice [J]. Chin J Clin Phamacol, 2014, 30 (8): 708-711. |
| [12] | Zhang WJ, Wang JY, Li H, et al. Novel application of natural anisole compounds as enhancers for transdermal delivery of ligustrazine [J]. Am J China Med, 2015, 43 (6): 1231-1246. |
| [13] | Cai J, Pan R, Jia X, et al. The combination of astragalus membranaceous and ligustrazine ameliorates micro-hemorrhage by maintaining blood-brain barrier integrity in cerebrally ischemic rats [J]. J Ethnopharmacol, 2014, 158 (Pt A): 301-309. |
| [14] | SUN Long-fei, AN Dong-Qing. Research Progress on Mechanism of Inflammatory Signaling Pathway in Atherosclerosis and the Intervention of Traditional Chinese Medicine [J]. Chin J Arterioscler, 2015, 23 (11): 1177-1181. |
| [15] | LIU Chang, Qiu Xia, LIU Guo-dong. The inflammation mechanism of atherosclerotic and intervention effects of sodium ferulate [J]. Journal of Yangzhou University (Agricultural and Life Science Edition), 2012, 33 (1): 18-22. |
| [16] | Xuan Chang-bo, Wang Xian. The Study Survey of Traditional Chinese Medicine in Intervention of Vulnerable Atherosclerotic plaque [J]. Journal of Traditional Chinese Medicine, 2014, 55 (18): 1607-1610. |
| [17] | Wei Zheng, Wu Yong-xin, Liu lina, et al. Effects and mechanism of different doses of Rosuvastatin on expression of liver X receptor and caveolin-1 in cultured human monocyte-macrophage cells induced by oxidized low density lipoprotein [J]. Clinical Medicine of China, 2014, 30 (11): 1138-1141. |
| [18] | CHEN Fu-xin, WANG Lian-Kai. Effect of ferulic acid on cholesterol efflux in macrophage foam cell formation and potential mechanism [J]. China Journal of Chinese Materia Medica, 2015, 40 (3): 533-537. |
